您的位置: 首页 > 农业专利 > 详情页

TUMOR THERAPY BY BISPECIFIC ANTIBODY PRETARGETING
专利权人:
Immunomedics; Inc.
发明人:
BOERMAN, Otto C.,HESKAMP, Sandra,CHANG, Chien-Hsing,MCBRIDE, William J.,GOLDENBERG, David M.
申请号:
EP15877299
公开号:
EP3242889A4
申请日:
2015.11.16
申请国别(地区):
EP
年份:
2018
代理人:
摘要:
The present invention relates to methods and compositions for pretargeting delivery of alpha-emitting radionuclides, such as 213Bi or 225AC to a target cell or tissue, such as a cancer cell or a tumor. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody comprising at least one binding site for a tumor-associated antigen (TAA) and at least one binding site for a hapten and b) administering a hapten-conjugated targetable construct that is labeled with an alpha-emitting radionuclide. More preferably, the bispecific antibody is rapidly internalized into the target cell, along with the radionuclide. In most preferred embodiments, the bispecific antibody is made as a dock-and-lock (DNL) complex.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充